ARTICLE | Clinical News
Dirucotide: Development discontinued
January 4, 2010 8:00 AM UTC
BioMS will discontinue development of dirucotide following a review of Phase III data. In September, Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) returned rights for the program to BioMS after di...